Infections are responsible for a large part of the morbidity and mortality after BMT because of the sustained impairment of host defenses. We report a case of cutaneous infection caused by Mycobacterium szulgai in a boy who underwent BMT with marrow from a matched unrelated donor.
cutaneous infection; Mycobacterium szulgai BMT recipients are susceptible to a wide variety of unusual pathogens for a long time after BMT because of the sustained impairment of host defenses. Since the inflammatory response is attenuated in immunocompromised hosts, infections with nontuberculous mycobacteria (NTM), which are characterized by their protean clinical manifestations, might be difficult to recognize. At our center, a boy contracted a cutaneous infection shortly after a successful BMT. The cause of the infection remained elusive for several months, but eventually proved to be caused by an unusual human pathogen, Mycobacterium szulgai.
M. szulgai was first identified as a distinct species in 1972 and may produce a wide range of clinical syndromes. 1, 2 Cutaneous infection caused by M. szulgai has previously been described in five cases. [3] [4] [5] [6] [7] To our knowledge, it has never been described in a BMT recipient before.
Methods
Mycobacterial culture was performed after decontamination according to the sodium lauryl sulfate method, with the addition of N-acetyl-l-cysteine 0.5%. The material was centrifuged at 3500 Â g and washed with phosphate buffer, pH 6.8. Of the homogenized specimen, 0.2-0.3 ml was inoculated into one tube containing conventional Lo¨w-enstein-Jensen medium (LJ) and one containing LJ with 0.6% sodium pyruvate. The tubes were incubated for 7 weeks at 371C and if from superficial lesions at 301C too and weekly examined for growth. Species diagnosis of NTM was attained by 16S rRNA gene sequencing, supplemented with phenotypical characterization (pigment production and growth velocity). Sensitivity testing was performed using the BACTEC s broth system.
Case report
A 4-year-old boy with T-cell leukemia in third complete remission underwent BMT with marrow from a matched unrelated donor at the University Hospital of Uppsala in May 1998. The first and second remissions had been promptly achieved. The third remission was achieved only after lengthy cytostatic treatment, resulting in prolonged granulocytopenia and recurrent Pseudomonas aeruginosa infections of the middle ear, which were treated with oral ciprofloxacin. During the conditioning prior to BMT, paronychia of the right toe was noted and was treated with disinfectant topically. BMT was well tolerated. There were no infections and no evidence of graft-versus-host disease (GVHD). He was discharged 1 month after BMT. Infection prophylaxis consisted of oral fluconazole, acyclovir, trimetroprimsulfamethoxazole, and weekly infusions of immunoglobulin. Oral ciprofloxacin was also continued. Prophylaxis against GVHD consisted of cyclosporine A.
At 6 weeks after BMT pancytopenia was noted. Bone marrow investigation showed a hypoplastic marrow without signs of relapse. Despite extensive diagnostic work-up, no straightforward explanation for the pancytopenia was found, but human herpesvirus type 6 was suspected to be the cause since it was detected in one bone marrow aspirate. I.v. foscarnet was given for 2 weeks. He continued to have low white blood cell counts intermittently (polymorphonuclear cell count o0.5 Â 10 9 /l) for 6 more weeks, but was otherwise fit and well. At 12 weeks after BMT, a small lesion of the skin was noted at the paronychium of the right big toe. It progressed rapidly with swelling and redness of the entire toe. Tiny vesicles and pustules disseminated over the distal-medial aspect of the sole and dorsal surface of the foot. Two fluctuant, nontender masses were also noted in the right groin, the largest measuring 3 Â 3 Â 3 cm, with red-bluish discoloration of the covering skin. There was no fever or chills. C-reactive protein was normal and the erythrocyte sedimentation rate peaked at 22 mm. At this time his hemoglobin was 105 g/l and hematocrit 30%; total leukocyte count was 3.0 Â 10 9 /l, polymorphonuclear cell count 0.7 Â 10 9 /l, and platelet count 158 Â 10 9 /l. The only finding was coagulase-negative staphylococci in one culture from the toe. Treatment with i.v. cloxacillin was therefore instituted. The treatment was subsequently changed to a combination of valacyclovir and clindamycin, since beside the staphylococcal infection Herpes simplex virus infection was also suspected and drug susceptibility studies indicated resistance of the staphylococci to cloxacillin. Evulsion of the nail was also performed. Progression continued despite these measures and the right big toe grew turgid and spongy, eventually measuring about twice its usual size. The antibiotic treatment was again changed to a combination of vancomycin and meropenem. Eventually, 8 weeks after the lesion was first noted, biopsies from the right big toe and from the enlarged lymphatic gland in the right groin showed chronic inflammation with epithelioid cells granulomas with occasional Langhans' giant cells. No acidfast bacilli were demonstrated by fluorescent microscopy using auramine stain. Skin testing with PPD-tuberculin or mycobacterial sensitins was not performed. Since mycobacterial infection was suspected, the treatment was changed to i.v. rifampicin 220 mg once daily. Cultures of specimens from the groin and toe were reported to grow NTM and hence the treatment was changed to oral rifampicin 300 mg once daily and ethambutol 400 mg once daily. The bacteriological diagnosis was M. szulgai. The drug susceptibility studies indicated that the strain was susceptible to amikacin, ciprofloxacin, ethambutol, claritromycin, rifampicin, streptomycin but resistant to isoniazid and protionamid. The current treatment was therefore continued unchanged (see Figure 1) . The lesion healed very slowly but completely. After the CD4/CD8 ratio had normalized, the treatment was discontinued in August 1999, after 9 months duration. No adverse effects of the treatment were noted; color vision and liver function were normal. The skin infection has shown no sign of relapse during a follow-up of 3 years after transplantation. The only sequela was impaired sensory response to touch of the affected skin. The main current concern is a hearing impairment, probably because of the recurrent P. aeruginosa infections of the middle ear.
Discussion
M. szulgai is a slow growing, scotochromogenic (forming pigment in the dark), NTM, first identified as a distinct species in 1972. 1 It is an unusual human pathogen. 2 About 70% of reported cases concern lung infections, mostly in men with pre-existing pulmonary disease, but other infections have been documented as well, such as olecranon bursitis, cervical lymphadenitis, tenosynovitis, and osteomyelitis. Cutaneous infection caused by M. szulgai has previously been described in three patients on long-term corticosteroid therapy, in one patient with a T-cell deficiency, and in one immunocompetent child. [3] [4] [5] [6] [7] No case of M. szulgai has previously been described after BMT. Diagnosis is based on culture and histopathology that shows typical granulomas without caseation.
M. szulgai is thought often to be clinically significant, and treatment should always be considered. Owing to the limited clinical experience, the optimal choice of drug, dose, and duration of treatment has yet to be defined. It must therefore be determined individually from susceptibility testing, clinical response, and assessment of immune status. 8 Recently, successful treatment of a cutaneous infection caused by M. szulgai using clarithromycin was described. 7 However, the use of more than one drug is often preferred. There is no evidence of human-to-human transmission of M. szulgai and its source is in the environment. It is not clear how our patient contracted the infection, but the paronychia detected during conditioning was obviously a possible portal of entry. He was discharged during summer time and his parents related that he often rode his bike barefoot and then easily scratched them. The summer was unusually rainy that year and it is possible that he dipped his injured feet into rain puddles that may serve as a natural habitat for M. szulgai.
Infections are responsible for a large part of the morbidity and mortality after BMT because of the sustained impairment of host defenses. Most severe infections occur early after BMT, but complete reconstitution of host defenses may take up to a year, sometimes further delayed by the advent of GVHD. Our patient did not develop GVHD, but the data suggest that the immune disparity may be important in its own right and that recipients of unrelated donor transplants may be more susceptible to late infections compared to recipients of related donor transplants, irrespective of whether GVHD Figure 1 The right foot of the patient 9 months after BMT.
Skin infection caused by M. Szulgai P Frisk et al develops. 9 Our patient also had prolonged neutropenia post-transplant that may have predisposed him to late infections. Owing to the severely impaired immunity after BMT, a high incidence of mycobacterial infections would be expected. In a retrospective review comprising 2241 patients, mycobacterial infections were found in only 11 patients (0.49%), however. 10 Two cases of M. tuberculosis were documented, the remainder being various NTM species. The predominant sites of infection were skin structures immediately adjacent to indwelling catheters.
Since the inflammatory response may be attenuated in the immunocompromised host and the resulting nonspecific manifestations may be caused by many other possible agents, mycobacterial infections may be difficult to recognize. Even though mycobacterial infections probably are rare after BMT, a high index of suspicion is therefore warranted and treatment should be promptly initiated once adequate material for diagnosis has been secured.
